Gilead to launch human trials by inhalation in the form of remedsivir to treat the coronavirus


Gilead Sciences is the launch of human trials for an inhaled form of its antiviral drug, remdesivir, to treat coronavirus patients, the company announced Monday.

Remdesivir is currently administered intravenously, which means patients must be treated at the hospital.

But at the same time its own research and from the National Institutes of Health (NIH) of the study suggest that providing the drug earlier, before the patient is seriously ill, could further improve the chances of survival and recovery time.

In addition to his work to test a form of drug that could be given to using a nebulizer, Gilead has promised to make more than two million courses of FDA-authorized drugs by the end of the year.

Gilead Sciences has the intention to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start testing a more easy-to-use inhaled version in August, the company said Monday.

Gilead will begin human trials of an inhalable version of its IV antiviral drug remdesivir in healthy volunteers during the month of August. The inhaled form could treat COVID-19 patients at home

Remdesivir was the first drug to demonstrate efficacy against COVID-19 in human trials, and its use in cases of emergency has been permitted by several countries, including the united States.


Remdesivir was developed by Gilead Sciences to treat the Ebola virus, the deadly hemorrhagic fever that emerged in West Africa in 2014.

The Ebola virus, as COVID-19, is caused by a virus, and scientists are currently testing remdesivir to treat coronavirus patients, but it is too early to know if the drug works or not.

Remdesivir produced encouraging results earlier this year when he showed promise for the prevention and treatment of MERS – another coronavirus in rhesus monkeys.

The drug seems to help stop the replication of viruses, such as coronavirus and the Ebola virus as.

This is not entirely clear how the drug accomplishes this feat, but it seems to stop the virus’s genetic material, RNA, to be able to copy itself.

That, in turn, prevents the virus from being able to proliferate inside the body of the patient.

NIH researchers in charge of the macaque study recommends moving on to human trials with the novel coronavirus.

Scientists have listened to, and of the human trials for remdesivir was first started in Nebraska.

More recently, researchers test the drug at the University of Chicago reported that most of the 125-COVID-19 patients that they had teated with the drug had been discharged from the hospital, according to Stat News.

Two patients died during the trial.

Gilead has established licensing agreements with nine generic drugmakers to ramp up the supply of remdesivir, Chief Executive officer Daniel O’day said in a press release.

It comes after the discovery that the government of the united states supply of remdesivir, given earlier this year by Gilead, is in the process of execution by the next month.

Although states like New York, which has been hit hard and early by the coronavirus have managed to get their seizures somewhat under control, the points of the infection are already visible across nearly half of all AMERICAN states, in particular those in the South.

And as autumn approaches, the experts are concerned that the cold and the confluence with the seasonal flu could mean a major uptick in the number of cases to come.

Six months after coronavirus arrived in the united states, there is as yet no vaccine to prevent the infection and only remdesivir and convalescent plasma have emergency clearance from the FDA to treat COVID-19.

Gilead donated August 607,000 doses of remdesivir for the U.S. government after NIH testing showed that the drug improved the chances of survival of about 13 percent.

But with nearly 1,000 people still hospitalized for COVID-19 last week, according to the Centers for Disease Control and Prevention (CDC) – a figure that is probably an under-count the supply of the antiviral drug decreased rapidly.

In the early days of the epidemic of coronavirus in the united states, the main cause of concern is that hospital systems would be invaded by the coronavirus of patients, the course of fans, and worse deaths than what has been seen.

This crisis has been averted, but health officials would still like to see the number of hospital beds, monopolized by the coronavirus patients.

An inhalable form of remdesivir could help to ease the burden on the hospitals to go forward, as it would be delivered through a device called a nebulizer, which is commonly used to treat people with asthma.

Unfortunately, some of the ingredients of the medication, it would be too dangerous to give in pill form, because it could cause liver and kidney damage if injested.

This week, Gilead will start screening healthy volunteers for the first phase of human trials to see if the inhalation of the formula remdesivir is safe. Gilead has not said how many volunteers it will recruit.

If all goes well, the company plans to begin trials of treatment of COVID-19 patients in August.

Last week, Gilead has also announced the launch of trials to treat children with remdesivir, as well as adult trials combining the antiviral drug with other drugs.


Please enter your comment!
Please enter your name here